Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Timolol · 4 trials · 4 indications
Calculated as Baseline IOP minus Week 12 IOP, LOCF. IOP measured using 1 of 3 methods: Goldmann applanation tonometry (preferred method, if feasible), Perkins tonometry, or TonoPen. IOP was measured twice and if the measurements were less than or equal to (≤) 2 millimeters of mercury (mmHg) of each other, the mean of the 2 readings was recorded as the IOP at that time point. Otherwise, a third IOP measurement was taken and the median IOP recorded.
| Arm | Type | Description |
|---|---|---|
| Timolol | ACTIVE_COMPARATOR | - |
| latanoprost | EXPERIMENTAL | - |
| Fixed combination of latanoprost 0.005% and timolol 0.5% | EXPERIMENTAL | - |
| timolol 0.5% ophthalmic solution | ACTIVE_COMPARATOR | one drop in the morning and evening |
| latanoprost 0.005% ophthalmic solution | ACTIVE_COMPARATOR | placebo in the morning and latanoprost .005% in the evening |
| PhXA41 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Timolol | DRUG | Timolol 0.5% dosed twice-daily |
| latanoprost | DRUG | Latanoprost 0.005% ophthalmic solution dosed once-daily |
| i. Fixed combination of latanoprost 0.005% and timolol 0.5% | DRUG | one drop in the morning and placebo in the evening |
| timolol 0.5% ophthalmic solution | DRUG | one drop in the morning and evening |
| latanoprost 0.005% ophthalmic solution | DRUG | placebo in the morning and latanoprost .005% in the evening |
| PhXA41 | DRUG | One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle. |
Inclusion Criteria: * Male or female of 18 years of age or under * Diagnosis of glaucoma * IOP of 22 mmHg or above in at least 1 eye Exclusion Criteria: * Require surgery for acute angle closure * Have had prior cyclodestructive procedures * Have a history of ocular trauma or surgery in either ey...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Timolol is used for the treatment of glaucoma, ocular hypertension, and open angle glaucoma. It is an ophthalmic medication being developed by Pfizer, Inc. for these conditions, which involve elevated pressure within the eye that can damage the optic nerve.
Timolol is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 3 clinical development for the treatment of glaucoma and related eye conditions.
Timolol is in Phase 3 clinical development. It is an investigational drug for the treatment of glaucoma, ocular hypertension, and open angle glaucoma. It has not been approved by regulatory authorities and remains under clinical investigation.
Timolol has been studied in several completed Phase 3 trials, including NCT00716859 in pediatric subjects with glaucoma, NCT00751049 in patients with open angle glaucoma or ocular hypertension in the UK, NCT00751062 in patients in Scandinavia, and NCT00856622 in Germany.
Timolol is a beta-blocker that works by reducing the production of aqueous humor in the eye, thereby lowering intraocular pressure. This mechanism helps to treat conditions like glaucoma and ocular hypertension by decreasing the pressure that can damage the optic nerve.
Timolol is in Phase 3 clinical development, with all completed trials showing it is being studied for glaucoma, ocular hypertension, and open angle glaucoma. It is an investigational small molecule developed by Pfizer, Inc., and is not yet approved for commercial use.